National Pharmaceutical Pricing Authority brings 42 non-scheduled cancer drugs under price control, caps trade margin at 30%

New Delhi: The government has decided to bring 42 non-scheduled anti-cancer drugs under price control, capping trade margin at 30 percent, an official statement on Wednesday said. The National Pharmaceutical Pricing Authority (NPPA) has invoked extraordinary powers in public interest, under Para 19 of the Drugs (Prices Control) Order, 2013 to bring 42 non-scheduled anti-cancer drugs under price control through trade margin rationalisation, the statement said. “Invoking paragraph 19 of DPCO, 2013, the government hereby puts a cap on trade margin of 30 percent and directs manufacturers to fix their retail price based on price at first point of sale of product… of the non-scheduled formulations containing any of the 42 drugs,” the Department of Pharmaceuticals (DOP) said in a notification As per data available with NPPA, the MRP for 105 brands will be reduced up to 85 percent entailing minimum saving of Rs 105 crore to consumers, it added. [caption id=“attachment_3929195” align=“alignleft” width=“380”]  Representational image. Agencies[/caption] Currently, 57 anti-cancer drugs are under price control as scheduled formulations Now 42 non-scheduled anti-cancer medicines have been selected for price regulation by restricting trade margin on the selling price (MRP) up to 30 percent, the notification said “These would cover 72 formulations and 355 brands as per data available with NPPA. More data is being collected from hospitals and manufacturers to finalise the list,” it added. The drug manufacturers have been given seven days to recalculate the prices and inform the NPPA, state drug controllers, stockists and retailers, it said. The revised prices shall come into effect from 8 March, it added The NPPA currently fixes prices of drugs placed in the National List of Essential Medicines (NLEM) under Schedule-I of the DPCO. So far, around 1000 drugs have been brought under price control under the initiative. Non-scheduled drugs are allowed an increase of up to 10 percent in prices every year, which is monitored by the NPPA.